CD40 combination therapy can shrink pancreatic tumors
A new combination of immunotherapy and chemotherapy for pancreatic cancer caused tumors to shrink in the majority of evaluable patients. The early findings provide hope that this strategy involving a CD40 antibody, a checkpoint inhibitor, and standard-of-care chemotherapy could be effective treatment.
FULL STORY AT Penn Medicine News →